13 / 20
Page 38
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
The cytoprotective role of autophagy inCYT997 treatedhumanhead andneck squamous cell carcinoma
Yong Teng
Augusta University, USA
H
ead and neck squamous cell carcinomas (HNSCC)
exhibiting resistance to molecular-targeted therapeutics
poses a challenge to their effective clinical management
and alternate treatment strategies are actively sought to
improve results. CYT997, a novel microtubule-disrupting
agent, has shown anticancer activity in prostate cancer
and other cancer types by inhibiting tubulin polymerization
and disrupting cellular microtubules. Here, we report that
CYT997 has considerable potential as a novel anticancer
agent for HNSCC. CYT997 effectively abrogates mTOR
signaling and induces significant cytotoxicity in HNSCC
cells. Consequently, CYT997 treatment inhibits cell viability,
migration and invasion and induces autophagy-associated
apoptosis. CYT997 also suppresses tumor growth of HNSCC
in a mouse xenograft model. Combined treatment with
CYT997 and the autophagy inhibitor HCQ, but not 3-MA,
overcomes autophagy blocked apoptosis and augments the
anticancer activity of CYT997
in vitro
and
in vivo
, suggesting
that inhibition of mTOR-dependent autophagy sensitizes
HNSCC cells to CYT997-induced apoptotic death. These
findings underline the importance of autophagy in the
anticancer activity of CYT997 and suggest that CYT997 may
represent a potential therapeutic approach to treat HNSCC
and pharmacologic autophagy blockade may enhance its
efficacy. Therefore, our study has significant impact on the
design and execution of effective therapy of patients with
HNSCC.
Speaker Biography
Yong Teng was largely engaged in illustrating cancer metastatic signaling cascades and
developing animal disease models for gene functional analysis and drug evaluation.
Through his team work, he has identified several new molecular targets and signaling
pathways which control cancer progression and metastasis and developed several
novel anticancer strategies by modulating them. He is trying to bridge three major
research themes, tumor microenvironment, autophagic survival and tumor metastasis,
with an emphasis on a few central regulators. His ongoing projects seek to shift
current research and clinical practice paradigm, which will directly impact the future
development of effective therapy for cancer patients.
e:
yteng@augusta.edu